Literature DB >> 19265183

Levetiracetam for managing neurologic and psychiatric disorders.

Muhammad U Farooq1, Archit Bhatt, Arshad Majid, Rishi Gupta, Atul Khasnis, Mounzer Y Kassab.   

Abstract

PURPOSE: The role of levetiracetam in different epileptic, nonepileptic, neurologic, and psychiatric disorders is discussed.
SUMMARY: Levetiracetam, an antiepileptic drug (AED), was first approved as an adjunctive therapy for the treatment of partial epilepsy in adults. It is currently being used in the treatment of multiple seizure disorders, including generalized tonic-clonic; absence; myoclonic, especially juvenile myoclonic; Lennox-Gastaut syndrome; and refractory epilepsy in children and adults. Data are emerging on possible uses of levetiracetam outside the realm of epilepsy because of its unique mechanisms of action. There is preliminary evidence about the efficacy of levetiracetam in the treatment of different psychiatric disorders, including anxiety, panic, stress, mood and bipolar, autism, and Tourette's syndrome. The most serious adverse effects associated with levetiracetam use are behavioral in nature and might be more common in patients with a history of psychiatric and neurobehavioral problems.
CONCLUSION: Levetiracetam is an effective AED with potential benefits in other neurologic and psychiatric disorders. The benefit-risk ratio in an individual patient with a specific condition should be used to determine its optimal use. Levetiracetam's use in nonepileptic conditions is not recommended until more data become available from larger trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265183     DOI: 10.2146/ajhp070607

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  11 in total

1.  Radiosynthesis of (11)C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression.

Authors:  Hancheng Cai; Thomas J Mangner; Otto Muzik; Ming-Wei Wang; Diane C Chugani; Harry T Chugani
Journal:  ACS Med Chem Lett       Date:  2014-08-19       Impact factor: 4.345

2.  Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications.

Authors:  Tyler M Lee; Carolyn L Villareal; Lisa M Meyer
Journal:  Hosp Pharm       Date:  2019-12-13

3.  Levetiracetam as an alternative therapy for Tourette syndrome.

Authors:  M A Martínez-Granero; A García-Pérez; F Montañes
Journal:  Neuropsychiatr Dis Treat       Date:  2010-06-24       Impact factor: 2.570

4.  Prediction Tools for Psychiatric Adverse Effects After Levetiracetam Prescription.

Authors:  Colin B Josephson; Jordan D T Engbers; Nathalie Jette; Scott B Patten; Shaily Singh; Tolulope T Sajobi; Deborah Marshall; Yahya Agha-Khani; Paolo Federico; Aaron Mackie; Sophie Macrodimitris; Brienne McLane; Neelan Pillay; Ruby Sharma; Samuel Wiebe
Journal:  JAMA Neurol       Date:  2019-04-01       Impact factor: 18.302

5.  Commentary.

Authors:  Roshan Bhad
Journal:  J Neurosci Rural Pract       Date:  2014-07

6.  Apparent dose-dependent levetiracetam-induced de novo major depression with suicidal behavior.

Authors:  Kenneth R Kaufman; Viwek Bisen; Aphrodite Zimmerman; Anthony Tobia; Ram Mani; Stephen Wong
Journal:  Epilepsy Behav Case Rep       Date:  2013-08-13

7.  Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions.

Authors:  William R Garnett; Erik K St Louis; Thomas R Henry; Thomas Bramley
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

Review 8.  Mechanisms of levetiracetam in the control of status epilepticus and epilepsy.

Authors:  Laxmikant S Deshpande; Robert J Delorenzo
Journal:  Front Neurol       Date:  2014-01-31       Impact factor: 4.003

9.  NEDD: a network embedding based method for predicting drug-disease associations.

Authors:  Renyi Zhou; Zhangli Lu; Huimin Luo; Ju Xiang; Min Zeng; Min Li
Journal:  BMC Bioinformatics       Date:  2020-09-17       Impact factor: 3.169

10.  Integration of postmortem amygdala expression profiling, GWAS, and functional cell culture assays: neuroticism-associated synaptic vesicle glycoprotein 2A (SV2A) gene is regulated by miR-133a and miR-218.

Authors:  Magdalena Jurkiewicz; Dirk Moser; Antonius Koller; Lei Yu; Emily I Chen; David A Bennett; Turhan Canli
Journal:  Transl Psychiatry       Date:  2020-08-24       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.